Search

Your search keyword '"Mikołajczak, Renata"' showing total 213 results
Start Over Author "Mikołajczak, Renata"
213 results on '"Mikołajczak, Renata"'

7. PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties

Author

Garnuszek, Piotr, primary, Karczmarczyk, Urszula, primary, Maurin, Michał, primary, Sikora, Arkadiusz, primary, Zaborniak, Jolanta, primary, Pijarowska-Kruszyna, Justyna, primary, Jaroń, Antoni, primary, Wyczółkowska, Monika, primary, Wojdowska, Wioletta, primary, Pawlak, Dariusz, primary, Lipiński, Piotr F. J., primary, and Mikołajczak, Renata, primary

Published
2021
Full Text
View/download PDF

10. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients

Author

Maina, Theodosia, Konijnenberg, Mark W., KolencPeitl, Petra, Garnuszek, Piotr, Nock, Berthold A., Kaloudi, Aikaterini, Kroselj, Marko, Zaletel, Katja, Maecke, Helmut, Mansi, Rosalba, Erba, Paola, von Guggenberg, Elisabeth, Hubalewska-Dydejczyk, Alicja, Mikolajczak, Renata, and Decristoforo, Clemens

Published
2016
Full Text
View/download PDF

11. Current state and prospects for the development of nuclear medicine in Poland.

Author

Teresińska, Anna, Mikołajczak, Renata, Jarząb, Barbara, Królicki, Leszek, Płachcińska, Anna, Braziewicz, Janusz, Kostkiewicz, Magdalena, Dziuk, Mirosław, Birkenfeld, Bożena, and Małkowski, Bogdan

Subjects
RADIOPHARMACEUTICALS, DIAGNOSTIC imaging, POSITRON emission tomography, RADIATION dosimetry, POSITRON emission tomography computed tomography, RADIOISOTOPES, NUCLEAR medicine, RADIOBIOLOGY, ORGANIZATIONAL change, COMMITTEES, RADIONUCLIDE imaging
Abstract

The aim of the report is to present the current state of equipment, radiopharmacy, dosimetry, and selected clinical applications, together with proposed new solutions and expected directions of development of classic nuclear medicine and positron emission tomography (PET). The statement presents the individual points of view of the members of the Commission for Nuclear Medicine of the Committee of Medical Physics, Radiobiology and Diagnostic Imaging of the Polish Academy of Sciences in the 2020-2023 term. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Quantitative assessment of radioactivity losses in the administration of therapeutic doses of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE.

Author

Cieszykowska, Izabela, Rybak, Paweł, Janiak, Tomasz, Żółtowska, Małgorzata, Ochman, Paweł, Steczek, Łukasz, Szczodry, Artur, Lenda-Tracz, Wioletta, Mikołajczak, Renata, and Garnuszek, Piotr

Subjects
RADIOISOTOPE therapy, RADIOPHARMACEUTICALS, RESEARCH funding, QUANTITATIVE research, DESCRIPTIVE statistics, INTRAVENOUS therapy, NEUROENDOCRINE tumors, DOSAGE forms of drugs, GENETIC techniques, RADIATION doses, CELL receptors, RADIOACTIVE elements, DRUG dosage, DRUG administration
Abstract

Background: Therapeutic radiopharmaceuticals [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE are used in peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. One of the factors determining the efficacy of such therapy is administering the radiopharmaceutical dose to the patients in a way consistent with treatment planning. This paper evaluates the loss of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE and their mixed doses during the administration to the patient either by direct infusion or by gravity method. Material and methods: The loss of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE, was assessed in tests simulating the administration procedures and during infusion to the patients performed at four clinical centres. One clinical centre used a direct infusion, and three others used a gravity method to administer radiopharmaceuticals to the patient. Results: In the direct infusion the highest radioactivity loss was 3.88% ± 0.49% (n = 3) and 3.76% ± 0.83% (n = 3) for [177Lu] Lu-DOTA-TATE infusion with radioactivity of 3.71 GBq ± 0.08 GBq (n = 3) and 1.06 GBq ± 0.08 GBq (n = 3), respectively, and 4.04% ± 0.40% (n = 5) for infusion of [90Y]Y-DOTA-TATE dose of 1.98 GBq ± 0.05 GBq (n = 5). In the gravity method administration of [177Lu]Lu-DOTA-TATE generated losses of up to 1.31% ± 0.46% (n = 16) for a dose of 7.45 GBq ± 0.06 GBq (n = 16) and 2.93% ± 1.64% (n = 8) for a dose of 3.78 GBq ± 0.05 GBq (n = 8). However, the infusion of the lowest doses of 0.95 GBq ± 0.01 GBq (n = 4) [177Lu]Lu-DOTA-TATE and 1.96 GBq ± 0.03 GBq (n = 8) [90Y]Y-DOTA-TATE resulted in higher loss of radiopharmaceuticals up to 6.00% ± 0.97% (n = 4) and 4.00% ± 1.57% (n = 8), respectively. Conclusions: Both investigated methods of radiopharmaceutical administration are associated with the loss of the radioactivity of radiopharmaceutical. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Polish Experience in Peptide Receptor Radionuclide Therapy

Author

Kunikowska, Jolanta, Królicki, Leszek, Sowa-Staszczak, Anna, Hubalewska-Dydejczyk, Alicja, Pawlak, Dariusz, Mikolajczak, Renata, Handkiewicz-Junak, Daria, Szaluś, Norbert, Kamiński, Grzegorz, Cwikla, Jaroslaw, Jakuciński, Maciej, Lukiewicz, Anna, Kowalska, Aldona, Gut, Pawel, Baum, Richard P., editor, and Rösch, Frank, editor

Published
2013
Full Text
View/download PDF

21. Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

Author

Pach, Dorota, Sowa-Staszczak, Anna, Kunikowska, Jolanta, Królicki, Leszek, Trofimiuk, Małgorzata, Stefańska, Agnieszka, Tomaszuk, Monika, Głowa, Bogusław, Mikołajczak, Renata, Pawlak, Dariusz, Jabrocka-Hybel, Agata, and Hubalewska-Dydejczyk, Alicja B.

Published
2012
Full Text
View/download PDF

28. Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers.

Author

D'Onofrio, Alice, Silva, Francisco, Gano, Lurdes, Raposinho, Paula, Fernandes, Célia, Sikora, Arkadiusz, Wyczółkowska, Monika, Mikołajczak, Renata, Garnuszek, Piotr, and Paulo, António

Subjects
PEPTIDE receptors, COMPANION diagnostics, PROOF of concept, MOIETIES (Chemistry), PHARMACOKINETICS, PANCREAS
Abstract

Several gastrin-releasing peptide receptor (GRPR) antagonists with improved in vivo behavior have been recently developed and tested in the clinic. However, despite the generally mild side effects of peptide receptor radionuclide therapy (PRRT), toxicity has been observed due to high doses delivered to nontarget tissues, especially in the kidneys and pancreas. Previous experiences with radiolabeled peptides opened a unique opportunity to explore GRPR pretargeting using clickable bombesin antagonists. Toward this goal, we used clickable DOTA-like radiocomplexes which have been previously evaluated by our group. We functionalized a potent GRPR antagonist with a clickable TCO moiety using two different linkers. These precursors were then studied to select the compound with the highest GRPR binding affinity and the best pharmacokinetics to finally explore the advantages of the devised pretargeting approach. Our results provided an important proof of concept toward the development of bioorthogonal approaches to GRPR-expressing cancers, which are worth investigating further to improve the in vivo results. Moreover, the use of clickable GRPR antagonists and DOTA/DOTAGA derivatives allows for fine-tuning of their pharmacokinetics and metabolic stability, leading to a versatile synthesis of new libraries of (radio)conjugates useful for the development of theranostic tools toward GRPR-expressing tumors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Selection of the first $^{99m}$ Tc-Labelled somatostatin receptor subtype 2 antagonist for clinical translation : preclinical assessment of two optimized candidates

Author

Fani, Melpomeni, Weingaertner, Viktoria, Kolenc Peitl, Petra, Mansi, Rosalba, Gaonkar, Raghuvir H., Garnuszek, Piotr, Mikołajczak, Renata, Novak, Doroteja, Simoncic, Urban, Hubalewska-Dydejczyk, Alicja, Rangger, Christine, Kaeopookum, Piriya, and Decristoforo, Clemens

Subjects
somatostatin receptor antagonist, SPECT/CT, neuroendocrine tumours, Tc-99m, SST2
Published
2021

36. Individual dosimetry and monitoring response to treatment in tandem PRRT with [177Lu/90Y]-DOTA-TATE

Author

Kacperski, Krzysztof, Budzyńska, Anna, Kubik, Agata, Pastusiak, Patrycja, Chalewska, Wioletta, Lenda-Tracz, Wioletta, Borkowska, Anna, Walecka-Mazur, Agata, Szczodry, Artur, Braziewicz, Janusz, Kołodziej, Maciej, Kamiński, Grzegorz, Dedecjus, Marek, Długosińska, Joanna, Januszkiewicz-Caulier, Joanna, Hubalewska-Dydejczyk, Alicja, Opalińska, Marta, Kowalska, Aldona, and Mikołajczak, Renata

Abstract

Introduction:The Duonen project aims to test the efficacy of tandem PRRT therapy of neuroendocrine tumors with DOTA-TATE labeled with 177Lu and 90Y radionuclides compared to conventional mono-radionuclide therapy using 177Lu with a fixed activity of 7.4 GBq. The paper presents the dosimetric procedure used and preliminary results obtained from the treatment of 40 patients and 113 cycles of therapy.

Published
2024
Full Text
View/download PDF

39. Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution

Author

Lankoff, Anna, primary, Czerwińska, Malwina, additional, Walczak, Rafał, additional, Karczmarczyk, Urszula, additional, Tomczyk, Kamil, additional, Brzóska, Kamil, additional, Fracasso, Giulio, additional, Garnuszek, Piotr, additional, Mikołajczak, Renata, additional, and Kruszewski, Marcin, additional

Published
2021
Full Text
View/download PDF

45. Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of 177Lu- and 90Y-Rituximab in Xenografted Mice

Author

Karczmarczyk, Urszula, Wojdowska, Wioletta, Mikołajczak, Renata, Maurin, Michał, Laszuk, Ewa, and Garnuszek, Piotr

Subjects
Animal study, 177Lu and 90Y, DOTA chelator, Original Article, Rituximab, neoplasms, Anti-CD20, Radiolabeling
Abstract

This work presents a comparative biological evaluation of 90Y- and 177Lu- labelled DOTA-SCN and DOTA-NHS conjugated to Rituximab in tumour-bearing mice. Two DOTA derivatives, p-SCN-Bn-DOTA and DOTA-NHS-ester were conjugated to Rituximab and then freeze-dried kit formulations were prepared, as previously described (1). Tissue distribution was investigated in tumour-bearing (Raji s.c.) male Rj: NMRI-Foxn1nu/Foxn1nu mice at different time points after administration of 177Lu-DOTA-Rituximab or 90Y-DOTA-Rituximab (6 MBq/10 μg per mouse). In addition, tumour images were acquired with a PhotonIMAGERTM after injection of 90Y-DOTA (SCN)-Rituximab. All radioimmunoconjugates were obtained with high radiolabelling yield (RCP > 98%) and specific activity of ca. 0.6 GBq/mg. The conjugates were stable in human serum and in 0.9% NaCl; however, progressive aggregation was observed with time, in particular for DOTA -(SCN) conjugates. Both 177Lu- and 90Y-DOTA -(SCN)-Rituximab revealed slow blood clearance. The maximum tumour uptake was found 72 h after injection of 177Lu-DOTA -(SCN)-Rituximab (9.3 ID/g). A high radioactivity uptake was observed in liver and spleen, confirming the hepatobiliary excretion route. The results obtained by the radioactive optical imaging harmonize with those from the biodistribution study.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results